Overview

Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma

Status:
Completed
Trial end date:
2016-11-04
Target enrollment:
Participant gender:
Summary
Randomized trial to determine if neo-adjuvant subcutaneous GM-CSF restores the host regional lymph node immunity
Phase:
Phase 4
Details
Lead Sponsor:
Mayo Clinic
Treatments:
Sargramostim